Comparative effectiveness and tolerance of treatments for Helicobacter pylori: Systematic review and network meta-analysis

BMJ (Online)

Volumn 351, Issue , 2015, Pages

  Li, Bao Zhu ^a   Threapleton, Diane Erin ^b   Wang, Ji Yao ^c   Xu, Jian Ming ^a   Yuan, Jin Qiu ^b   Zhang, Chao ^a   Li, Peng ^a   Ye, Qian Ling ^a   Guo, Biao ^a   Mao, Chen ^b   Ye, Dong Qing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROIMIDAZOLE; AMOXICILLIN; CLARITHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RANITIDINE BISMUTH CITRATE; 4-NITROIMIDAZOLE; ANTIINFECTIVE AGENT; NITROIMIDAZOLE DERIVATIVE;

ABDOMINAL PAIN; COMPARATIVE EFFECTIVENESS; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; EPIGASTRIC PAIN; ERADICATION THERAPY; HEADACHE; HELICOBACTER INFECTION; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TASTE DISORDER; VOMITING; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LEVOFLOXACIN; METRONIDAZOLE; NITROIMIDAZOLES; PROBIOTICS; PROTON PUMP INHIBITORS;

EID: 84942598716     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h4052     Document Type: Review

References (50)

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311-5.
2. Testerman TL, Morris J. Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. World J Gastroenterol 2014;20:12781-808.
3. Linz B, Balloux F, Moodley Y, et al. An African origin for the intimate association between humans and Helicobacter pylori. Nature 2007;445:915-8.
4. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010;362:1597-604.
5. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection. the Maastricht IV/Florence consensus report. Gut 2012;61:646-64.
6. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013;347:f4587.
7. Georgopoulos SD, Papastergiou V, Karatapanis S. Current options for the treatment of Helicobacter pylori. Expert Opin Pharmacother 2013;14:211-23.
8. Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of Helicobacter pylori infection. Helicobacter 2014;19(Suppl 1):1-5.
9. Fakheri H, Bari Z, Aarabi M, Malekzadeh R. Helicobacter pylori eradication in West Asia: a review. World J Gastroenterol 2014;20:10355-67.
10. Den Hollander WJ, Holster IL, Den Hoed CM, et al. Ethnicity is a strong predictor for Helicobacter pylori infection in young women in a multi-ethnic European city. J Gastroenterol Hepatol 2013;28:1705-11.
11. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 consensus report. Aliment Pharmacol Ther 2002;16:167-80.
12. Ungan M, Kulacoílu H, Kayhan B. Cure rates obtained with five different Helicobacter pylori eradication protocols in patients with duodenal ulcer: a prospective, open-label, randomized study in a primary care setting in Turkey. Curr Ther Res Clin Exp 2001:462-72.
13. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-53.
14. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report. Gut 2007;56:772-81.
15. Moayyedi P. Sequential regimens for Helicobacter pylori eradication. Lancet 2007;370:1010-2.
16. Valooran GJ, Kate V, Jagdish S, Basu D. Sequential therapy versus standard triple drug therapy for eradication of Helicobacter pylori in patients with perforated duodenal ulcer following simple closure. Scand J Gastroenterol 2011;46:1045-50.
17. Kadayifci A, Uygun A, Polat Z, et al. Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for Helicobacter pylori. Turk J Gastroenterol 2012;23:8-13.
18. Ye CL, Liao GP, He S, Pan YN, Kang YB, Zhang ZY. Levofloxacin and proton pump inhibitor-based triple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Pharmacoepidemiol Drug Saf 2014;23:443-55.
19. Du YQ, Su T, Fan JG, et al. Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection. World J Gastroenterol 2012;18:6302-7.
20. Song MJ, Park DI, Park JH, et al. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter 2010;15:206-13.
21. Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013;12:CD008337.
22. Dang Y, Reinhardt JD, Zhou X, Zhang G. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PLoS One 2014;9:e111030.
23. Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. Aliment Pharmacol Ther 2011;34:604-17.
24. Wang B, Wang YH, Lv ZF, et al. Efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter 2015;20:79-88.
25. Wang B, Lv ZF, Wang YH, et al. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis. World J Gastroenterol 2014;20:14973-85.
26. Gong EJ, Yun SC, Jung HY, et al. Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change? J Korean Med Sci 2014;29:704-13.
27. Stagg HR, Zenner D, Harris RJ, Munoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med 2014;161:419-28.
28. Yuan J, Zhang R, Yang Z, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol 2013;63:902-12.
29. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
30. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
31. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions, v. 5.1.0. Cochrane Collaboration. Updated March 2011. www.cochrane-handbook.org.
32. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomized controlled trials. National Institute for Health and Care Excellence. Updated April 2014. www.nicedsu.org.uk.
33. Dias S, Sutton AJ, Welton NJ, Ades AE. NICE DSU technical support document 3: heterogeneity: subgroups, meta-regression, bias and bias-adjustment. National Institute for Health and Care Excellence. Updated April 2012. www.nicedsu.org.uk.
34. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One 2013;8:e76654.
35. Zhu R, Chen K, Zheng YY, et al. Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. World J Gastroenterol 2014;20:18013-21.
36. Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion 2013;88:33-45.
37. Kim JS, Ji JS, Choi H, Kim JH. Sequential therapy or triple therapy for Helicobacter pylori infection in Asians: systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2014;38:118-25.
38. Ching SS, Sabanathan S, Jenkinson LR. Treatment of Helicobacter pylori in surgical practice: a randomised trial of triple versus quadruple therapy in a rural district general hospital. World J Gastroenterol 2008;14:3855-60.
39. Hung IF, Chan P, Leung S, et al. Clarithromycin-amoxycillincontaining triple therapy: a valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong? Helicobacter 2009;14:505-11.
40. Aydin A, Onder G, Akarca U, Tekin F, Tuncyurek M, Ilter T. Comparison of 1- and 2-week pantoprazole-based triple therapies in clarithromycin-sensitive and resistant cases. Eur J Intern Med 2007;18:496-500.
41. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012;5:23-34.
42. Wang ZH, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol 2013;47:25-32.
43. Urdaci MC, Bressollier P, Pinchuk I. Bacillus clausii probiotic strains: antimicrobial and immunomodulatory activities. J Clin Gastroenterol 2004;38:S86-90.
44. Zou J, Dong J, Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter 2009;14:97-107.
45. Erickson KL, Hubbard NE. Probiotic immunomodulation in health and disease. J Nutr 2000;130:403S-09S.
46. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007;146:556-63.
47. Wu DC, Hsu PI, Wu JY, et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol 2010;8:36-41 e1.
48. Liou JM, Chen CC, Chen MJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013;381:205-13.
49. Greenberg ER, Anderson GL, Morgan DR, et al. 14 day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011;378:507-14.
50. Loymans RJ, Gemperli A, Cohen J, et al. Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis. BMJ 2014;348:g3009.